vice president of U.S. advocacy and health equity at biopharmaceutical company Gilead Sciences, at the event. "There's a lot ...

Commissions do not affect our editors' opinions or evaluations. The term “black card” has come to symbolize an ultra-exclusive high-end credit card, referenced in pop culture as the ultimate ...

Environmental science is the multidisciplinary study of all aspects of the Earth’s physical and biological environments. It encompasses environmental chemistry, soil science, ecology ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to ...

This artist’s illustration depicts a dwarf galaxy that hosts an active galactic nucleus — an actively feeding black hole. In the background are many other dwarf galaxies hosting active black holes, as ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health ...

16 analysts have shared their evaluations of Gilead Sciences GILD during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the ...

The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release. Gilead Sciences, Inc. recently announced that the FDA accepted its new drug ...